☆ 4.7 Article

BKM120 inhibits malignant rhabdoid tumor of the kidney through induction of apoptosis and G0/G1 phase arrest

EUROPEAN JOURNAL OF PHARMACOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Extracranial rhabdoid tumours: Results of a SFCE series of patients treated with a dose compression strategy according to European Paediatric Soft tissue sarcoma Study Group recommendations

Maxime Enault et al.

Summary: Background and aims: This study retrospectively analyzed the effectiveness of the new treatment approach for extracranial malignant rhabdoid tumors in children in France. The results showed that the treatment regimen did not cause significant short-term toxicity, including in infants, and achieved favorable outcomes in patients meeting certain conditions. However, the prognosis remains poor for patients without complete tumor resection or with metastatic lesions.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Editorial Material Pharmacology & Pharmacy

Atypical teratoid rhabdoid tumor (ATRT): disease mechanisms and potential drug targets

Julian S. Rechberger et al.

EXPERT OPINION ON THERAPEUTIC TARGETS (2022)

Add to Collection

Article Endocrinology & Metabolism

PI3K inhibition by BKM120 results in anti-proliferative effects on corticotroph tumor cells

H. A. Oliveira et al.

Summary: Treatment with BKM120 showed anti-proliferative effects on corticotroph tumor cells, reducing cell viability and ACTH production. It also induced cell cycle arrest and inhibited the AKT signaling pathway.

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2022)

Add to Collection

Article Gastroenterology & Hepatology

Phase II study of BKM120 in patients with advanced esophageal squamous cell carcinoma (EPOC1303)

Takashi Kojima et al.

Summary: BKM120 monotherapy showed promising efficacy and manageable toxicity in patients with pretreated advanced esophageal squamous cell carcinoma (ESCC). Activation of the PI3K pathway was associated with good clinical response.

ESOPHAGUS (2022)

Add to Collection

Article Oncology

Molecular Heterogeneity in Pediatric Malignant Rhabdoid Tumors in Patients With Multi-Organ Involvement

Katherine E. Miller et al.

Summary: This study analyzed seven rhabdoid tumors from three pediatric patients using a multimodal molecular approach. The findings revealed SMARCB1 germline alterations in all patients and tumors, as well as different subgroups of rhabdoid tumors. The study also showed non-clonal origin of synchronous brain and kidney tumors, and suggested the likely origin of lung and abdominal metastasis. Other genetic events were identified in tumors but did not offer prognostic or therapeutic potential for rhabdoid tumors.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Review Pharmacology & Pharmacy

Targeting Akt/PKB in pediatric tumors: A review from preclinical to clinical trials

Bruno Toson et al.

Summary: This article reviews the application of Akt inhibitors in pediatric cancers. The study demonstrates the impact of Akt inhibition on tumorigenesis and suggests targeting the PI3K/Akt/mTOR signaling pathway as an effective approach for treating pediatric tumors.

PHARMACOLOGICAL RESEARCH (2022)

Add to Collection

Article Oncology

A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer

Yen-Shen Lu et al.

Summary: This study evaluated the efficacy and safety of alpelisib or buparlisib in combination with tamoxifen and goserelin in premenopausal patients with HR+, HER2(-) ABC. The RP2Ds of alpelisib and buparlisib were established at 350 mg and 100 mg, respectively, with no unexpected safety findings. The progression-free survival was slightly longer in the alpelisib group compared to the buparlisib group.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Dermatology

Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3Kα/δ and HDAC

Chi-Heng Wu et al.

Summary: Cutaneous T-cell lymphoma is a type of non-Hodgkin lymphoma that starts in the skin and spreads systemically, with limited treatment options. Researchers identified PI3K inhibitor BKM120 as potentially effective in the disease through high-throughput screening and patient-derived xenograft mouse models, and demonstrated the importance of PI3K-delta in tumor proliferation.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2021)

Add to Collection

Article Oncology

AP-2α Regulates S-Phase and Is a Marker for Sensitivity to PI3K Inhibitor Buparlisib in Colon Cancer

Anna C. Beck et al.

Summary: Loss of AP-2 alpha in colon cancer leads to prolonged cell cycle progression through altered activation of AKT, resulting in resistance to the PI3K inhibitor Buparlisib. AP-2 alpha serves as a marker for response to PI3K inhibitors.

MOLECULAR CANCER RESEARCH (2021)

Add to Collection

Article Cell Biology

BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair

Shaolu Zhang et al.

Summary: This study demonstrated synergistic anticancer effects of PARP inhibitor and PI3K inhibitor on GBM cells, affecting HR molecule expression, repair efficiency, and apoptosis induction. The combination therapy showed significantly increased anti-tumor efficacy in cell and animal models, with complemented DNA damage response and drug accumulation. This combination therapy might represent a promising therapeutic approach for GBM.

CELL DEATH & DISEASE (2021)

Add to Collection

Article Respiratory System

Dual targeting of MEK and PI3K effectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with different genetic backgrounds

Ge-Ping Qu et al.

Summary: This study evaluated the effects of dual targeting of MEK and PI3K in human EGFR-TKI resistant NSCLC cell lines. Dual targeting efficiently inhibited cell proliferation, induced apoptosis and cell cycle distribution, and decreased phosphorylation of key proteins. Different mutation and amplification status in genes EGFR, K-RAS, PIK3CA, and MET led to varying sensitivity to different drug combinations, demonstrating promising therapeutic potentials for EGFR-TKI resistant NSCLC, especially in K-RAS and PIK3CA mutants.

BMC PULMONARY MEDICINE (2021)

Add to Collection

Article Oncology

PI3K Promotes Basal Cell Carcinoma Growth Through Kinase-Induced p21 Degradation

Rachel Y. Chow et al.

Summary: The PI3K pathway is highly expressed in BCC and inhibition of PI3K activity reduces cell proliferation and HH signaling in BCC cells. Treatment with a PI3K inhibitor in mouse BCCs slows tumor cell growth without affecting HH signaling significantly. PI3K promotes BCC tumor growth through kinase-induced p21 degradation without altering HH signaling.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Targeting PI3K/Akt signal transduction for cancer therapy

Yan He et al.

Summary: The PI3K/Akt signaling pathway plays a crucial role in cancer, and targeting inhibitors against it may aid in drug discovery. Additionally, combining pathway inhibitors with other cancer treatment strategies could be an effective approach to solving therapeutic dilemmas.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

Add to Collection

Article Multidisciplinary Sciences

An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity

Camilla Calandrini et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Article Oncology

A high-throughput drug combination screen identifies an anti-glioma synergism between TH588 and PI3K inhibitors

Zhen Chen et al.

CANCER CELL INTERNATIONAL (2020)

Add to Collection

Article Oncology

Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck

Hye Ryun Kim et al.

BRITISH JOURNAL OF CANCER (2020)

Add to Collection

Review Pharmacology & Pharmacy

Emerging therapeutic targets for the treatment of malignant rhabdoid tumors

Karolina Nemes et al.

EXPERT OPINION ON THERAPEUTIC TARGETS (2018)

Add to Collection

Review Oncology

Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism

D. Morel et al.

ANNALS OF ONCOLOGY (2017)

Add to Collection

Article Oncology

Assessment of the Treatment Approach and Survival Outcomes in a Modern Cohort of Patients With Atypical Teratoid Rhabdoid Tumors Using the National Cancer Database

Benjamin W. Fischer-Valuck et al.

CANCER (2017)

Add to Collection

Article Oncology

Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma

Ankita Gupte et al.

CLINICAL CANCER RESEARCH (2015)

Add to Collection

Review Chemistry, Multidisciplinary

PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes

Ipsita Pal et al.

ACTA PHARMACOLOGICA SINICA (2012)

Add to Collection

Article Oncology

Clinicopathologic prognostic factors in childhood atypical teratoid and rhabdoid tumor of the central nervous system

Christelle Dufour et al.

CANCER (2012)

Add to Collection

Article Oncology

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

Sauveur-Michel Maira et al.

MOLECULAR CANCER THERAPEUTICS (2012)

Add to Collection

Article Oncology

Malignant Rhabdoid Tumours of the Kidney (MRTKs), Registered on Recent SIOP Protocols From 1993 to 2005: A Report of the SIOP Renal Tumour Study Group

Marry M. van den Heuvel-Eibrink et al.

PEDIATRIC BLOOD & CANCER (2011)

Add to Collection

Article Chemistry, Medicinal

Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer

Matthew T. Burger et al.

ACS MEDICINAL CHEMISTRY LETTERS (2011)

Add to Collection

Article Oncology

Systematic analysis of the antiproliferative effects of novel and standard anticancer agents in rhabdoid tumor cell lines

Henning Luenenbuerger et al.

ANTI-CANCER DRUGS (2010)

Add to Collection

Article Pharmacology & Pharmacy

Application of connectivity mapping in predictive toxicology based on gene-expression similarity

Joshua L. Smalley et al.

TOXICOLOGY (2010)

Add to Collection

Article Multidisciplinary Sciences

The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease

Justin Lamb et al.

SCIENCE (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.